| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8101582 | EYEVANCE | Topical ophthalmic compositions containing tobramycin and dexamethasone |
Dec, 2027
(4 years from now) | |
| US8450287 | EYEVANCE | Topical ophthalmic compositions containing tobramycin and dexamethasone |
Dec, 2027
(4 years from now) | |
| US7795316 | EYEVANCE | Topical ophthalmic compositions containing tobramycin and dexamethasone |
Aug, 2028
(4 years from now) | |
Tobradex St is owned by Eyevance.
Tobradex St contains Dexamethasone; Tobramycin.
Tobradex St has a total of 3 drug patents out of which 0 drug patents have expired.
Tobradex St was authorised for market use on 13 February, 2009.
Tobradex St is available in suspension/drops;ophthalmic dosage forms.
Tobradex St can be used as use of a combination of tobramycin and dexamethasone to treat ocular inflammation where an infection or risk of infection exists.
The generics of Tobradex St are possible to be released after 03 August, 2028.
Drugs and Companies using DEXAMETHASONE; TOBRAMYCIN ingredient
Market Authorisation Date: 13 February, 2009
Treatment: Use of a combination of tobramycin and dexamethasone to treat ocular inflammation where an infection or risk of infection exists
Dosage: SUSPENSION/DROPS;OPHTHALMIC
TOBRADEX ST family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic